Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 18/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673188 | 0.89 | GABRA5 (0.56) | GABRA5 | |
| SCHEMBL2673947 | 0.86 | GABRA5 (0.58) | GABRA5 | |
| SCHEMBL7799674 | 0.84 | GABRA5 (0.60) | GABRA5 | |
| SCHEMBL2673952 | 0.84 | GABRA5 (0.49) | GABRA5 | |
| SCHEMBL535794 | 0.82 | GABRA5 (0.76) | GABRA5GABRG2GABRB3 | |
| SCHEMBL286431 | 0.81 | GABRA5 (0.50) | GABRA5FFAR4GABRG2GABRB3KCNH2 | |
| SCHEMBL7521798 | 0.81 | GABRA5 (0.66) | GABRA5 | |
| SCHEMBL15252541 | 0.78 | GABRA5 (0.51) | GABRA5 | |
| SCHEMBL287851 | 0.77 | GABRA5 (0.48) | GABRA5FFAR4GABRG2GABRB3 | |
| SCHEMBL15252292 | 0.77 | GABRA5 (0.51) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398782-B1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8173652-B2 | Isoxazole-isoxazoles and isoxazole-isothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-08 | — | — | US | claimed |
| EP-2398782-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094669-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | claimed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | claimed |
| EP-2398782-B1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8173652-B2 | Isoxazole-isoxazoles and isoxazole-isothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2398782-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010094669-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885FFAR4 996/4885SMPD1 4587/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRA5 10/4885FFAR4 2107/4885SMPD1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.